» Articles » PMID: 26861115

Immunologic Response in Treatment-naïve HIV-2-infected Patients: the IeDEA West Africa Cohort

Overview
Journal J Int AIDS Soc
Date 2016 Feb 11
PMID 26861115
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Response to antiretroviral therapy (ART) among individuals infected with HIV-2 is poorly described. We compared the immunological response among patients treated with three nucleoside reverse-transcriptase inhibitors (NRTIs) to boosted protease inhibitor (PI) and unboosted PI-based regimens in West Africa.

Methods: This prospective cohort study enrolled treatment-naïve HIV-2-infected patients within the International Epidemiological Databases to Evaluate AIDS collaboration in West Africa. We used mixed models to compare the CD4 count response to treatment over 12 months between regimens.

Results: Of 422 HIV-2-infected patients, 285 (67.5%) were treated with a boosted PI-based regimen, 104 (24.6%) with an unboosted PI-based regimen and 33 (7.8%) with three NRTIs. Treatment groups were comparable with regard to gender (54.5% female) and median age at ART initiation (45.3 years; interquartile range 38.3 to 51.8). Treatment groups differed by clinical stage (21.2%, 16.8% and 17.3% at CDC Stage C or World Health Organization Stage IV for the triple NRTI, boosted PI and unboosted PI groups, respectively, p=0.02), median length of follow-up (12.9, 17.7 and 44.0 months for the triple NRTI, the boosted PI and the unboosted PI groups, respectively, p<0.001) and baseline median CD4 count (192, 173 and 129 cells/µl in the triple NRTI, the boosted PI and the unboosted PI-based regimen groups, respectively, p=0.003). CD4 count recovery at 12 months was higher for patients treated with boosted PI-based regimens than those treated with three NRTIs or with unboosted PI-based regimens (191 cells/µl, 95% CI 142 to 241; 110 cells/µl, 95% CI 29 to 192; 133 cells/µl, 95% CI 80 to 186, respectively, p=0.004).

Conclusions: In this observational study using African data, boosted PI-containing regimens had better immunological response compared to triple NRTI combinations and unboosted PI-based regimens at 12 months. A randomized clinical trial is still required to determine the best initial regimen for treating HIV-2 infected patients.

Citing Articles

Future of HIV2 and HIV2 +  1 Infected Patients Treated with Antiretrovirals Followed at the Day Hospital HIV Care Unit from 2011 to 2015.

Diallo I, Ouedraogo S, Sawadogo A, Ouedraogo G, Diendere E, Zoungrana J J Int Assoc Provid AIDS Care. 2022; 21:23259582221143675.

PMID: 36474417 PMC: 9732798. DOI: 10.1177/23259582221143675.


Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Raugi D, Ba S, Cisse O, Diallo K, Tamba I, Ndour C Clin Infect Dis. 2021; 72(3):369-378.

PMID: 33527119 PMC: 7850514. DOI: 10.1093/cid/ciaa277.


Long-term immunological responses to treatment among HIV-2 patients in Côte d'Ivoire.

Minchella P, Adje-Toure C, Zhang G, Tehe A, Hedje J, Rottinghaus E BMC Infect Dis. 2020; 20(1):213.

PMID: 32164565 PMC: 7069012. DOI: 10.1186/s12879-020-4927-x.


Performance evaluation of a laboratory developed PCR test for quantitation of HIV-2 viral RNA.

Jagodzinski L, Manak M, Hack H, Liu Y, Peel S PLoS One. 2020; 15(2):e0229424.

PMID: 32109949 PMC: 7048284. DOI: 10.1371/journal.pone.0229424.


[HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)].

Ba S, Dia-Badiane N, Hawes S, Fortes Deguenonvo L, Sall F, Ndour C Pan Afr Med J. 2019; 33:222.

PMID: 31692792 PMC: 6814923. DOI: 10.11604/pamj.2019.33.222.15771.


References
1.
Lhomme R, Nijland H, Gras L, Aarnoutse R, van Crevel R, Boeree M . Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS. 2009; 23(7):863-5. DOI: 10.1097/QAD.0b013e328329148e. View

2.
Chi B, Yiannoutsos C, Westfall A, Newman J, Zhou J, Cesar C . Universal definition of loss to follow-up in HIV treatment programs: a statistical analysis of 111 facilities in Africa, Asia, and Latin America. PLoS Med. 2011; 8(10):e1001111. PMC: 3201937. DOI: 10.1371/journal.pmed.1001111. View

3.
Peterson K, Jallow S, Rowland-Jones S, I de Silva T . Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. AIDS Res Treat. 2011; 2011:463704. PMC: 3065912. DOI: 10.1155/2011/463704. View

4.
Adje-Toure C, Cheingsong R, Garcia-Lerma J, Eholie S, Borget M, Bouchez J . Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS. 2003; 17 Suppl 3:S49-54. View

5.
Phillips A, Grabar S, Tassie J, Costagliola D, Lundgren J, Egger M . Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999; 13(15):2075-82. DOI: 10.1097/00002030-199910220-00010. View